SIGNIFICANT ITCH REDUCTION WITH OPZELURA1,2

4-POINT IMPROVEMENT IN ITCH (ITCH NRS4*) AT WEEK 81-3

Adapted from Papp K et al. doi:10.17632/ffx6nd5zyb.1. Licensed under CC BY 4.0.

>50% of patients

achieved a clinically meaningful improvement in itch at week 81*

  • Itch NRS4 response seen as early as day 3
    (18.4% OPZELURA vs 4.2% vehicle and 13.2% OPZELURA vs 0% vehicle)4

*Itch NRS4 is defined as the achievement of at least a 4-point improvement in daily itch on a 0- to 10-point scale, considered a clinically meaningful response; patients in the analysis had an NRS score ≥4 at baseline.1,2

In TRuE-AD1 and TRuE-AD2, respectively.1,2

BID=twice daily; EASI=Eczema Area and Severity Index; NRS=numeric rating scale.

Patient Isabelle

CHANGE IN ITCH NRS THROUGH WEEK 82

Adapted with permission from Papp K et al. J Am Acad Dermatol. doi:10.1016/j.jaad.2021.04.085.

ADDITIONAL EXPLORATORY
ANALYSIS
ADDITIONALEXPLORATORY ANALYSIS
Patient-reported change in Itch NRS score observed as early as day 1 and through day 562
Patient- reported change in itchNRS score observed as early as day 1 and through day 562
Patient Isabelle

Results were not adjusted for multiple comparisons.

BID=twice daily; EASI=Eczema Area and Severity Index; NRS=numeric rating scale.

Patient Isabelle

See EASI results >

References: 1. Opzelura. Prescribing Information. Incyte Corporation; 2021. 2. Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. Published online May 3, 2021. doi:10.1016/j.jaad.2021.04.085. 3. Papp K, Szepietowski JC, Kircik L, et al. Supplementary appendix, efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from two phase 3, randomized, double-blind studies. Mendeley Data. doi:10.17632/ffx6nd5zyb.1. 4. Data on file. Incyte Corporation. 2021.